Fundraising Fox
Amporin
Basel, CH · 2 known investors
Find your way into Amporin
Sign up to see every warm intro you have to Amporin
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Amporin team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Amporin Pharmaceuticals develops small-molecule drugs targeting toxic membrane pores formed by misfolded protein oligomers to treat neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Type 2 diabetes. The company aims to slow or halt disease progression and enable functional recovery in patients with protein misfolding and aggregation disorders.
Founders & leadership
KS
Kelvin StottCEO and CofounderKelvin Stott brings over 25 years of experience in pharmaceutical R&D strategy, drug discovery and development, portfolio management, and business operations across biotech startups and venture capital. He holds expertise in innovation and performance management, having worked in strategy consulting and led multiple drug development programs.
HS
Hervé SchaffhauserCSO and CofounderHervé Schaffhauser is a neuropharmacologist with over 20 years of drug development experience spanning target validation, preclinical studies, and Phase 1 clinical trials across pharmaceutical companies and startups. He has contributed to regulatory submissions and led preclinical programs involving small-molecule and large-molecule therapeutics including mRNA and AAV-based approaches.
Investors · 2
Kickfundlisted by KickfundBasel · $950K
How we know: the VCSheet dataset · Not right? Tell us
Venture KickreportedSchlieren-Zürich
How we know: funding news · press coverage · Not right? Tell us
Frequently asked questions
- What does Amporin do?
- Amporin Pharmaceuticals develops small-molecule drugs targeting toxic membrane pores formed by misfolded protein oligomers to treat neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Type 2 diabetes. The company aims to slow or halt disease progression and enable functional recovery in patients with protein misfolding and aggregation disorders.
- Who founded Amporin?
- Amporin was founded by Kelvin Stott, Hervé Schaffhauser, Daniel Umbricht.
- Who are Amporin's investors?
- Amporin's investors include Kickfund, Venture Kick.
- Where is Amporin headquartered?
- Amporin is headquartered in Basel, CH.